Abstract
Hodgkin lymphoma (HL) is highly responsive to combination chemotherapy and cure rates approach 75–80% with modern therapy, in which chemotherapy is almost always employed. In this chapter, we discuss the five standard chemotherapy regimens commonly used for the treatment of HL as well as their side-effect profiles, including late side effects, which may be seen many years after the administration of chemotherapy. Two new agents not yet commercially available will also be discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bennett MH, MacLennan KA, Vaughan HG et al (1991) Non-Hodgkin’s lymphoma arising in patients treated for Hodgkin’s disease in the BNLI: a 20-year experience. British National Lymphoma Investigation. Ann Oncol 2(Suppl 2):83–92
Bonadonna G, Zucali R, Monfardini S et al (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259
Canellos GP, Anderson JR, Propert KJ et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484
De Bruin ML, Huisbrink J, Hauptmann M et al (2008) Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 111:101–108
DeVita VT Jr, Serpick AA, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:881–895
Diehl V (2007) Hodgkin’s disease – from pathology specimen to cure. N Engl J Med 357:1968–1971
Diehl V, Sieber M, Ruffer U et al (1997) BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. The German Hodgkin’s Lymphoma Study Group. Ann Oncol 8:143–148
Diehl V, Franklin J, Pfreundschuh M et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395
Falorio S, Angrilli F, Fioritoni G (2008) Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma. Leuk Lymphoma 49:1087–1093
Fanale M, Bartlett NL, Forero-Torres A et al (2009) The antibody-drug conjugate Brentuximab Vedotin (SGN-35) induced multiple objective responses in patient with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study. Blood 114
Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494
Horning SJ, Hoppe RT, Breslin S et al (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20:630–637
Longo DL, Young RC, Wesley M et al (1986) Twenty years of MOPP therapy for Hodgkin’s disease. J Clin Oncol 4:1295–1306
Moskowitz AJ, Hamlin PA, Gerecitano J et al (2009) Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant. Blood 114
Nogova L, Rudiger T, Engert A (2006) Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. In: Berliner N, Linker C, Schiffer CA (eds) Hematology 2006. American Society of Hematology Education Program Book. American Society of Hematology, Washington
Pedersen-Bjergaard J, Specht L, Larsen SO et al (1987) Risk of therapy-related leukaemia and preleukaemia after Hodgkin’s disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 2:83–88
Rueffer U, Josting A, Franklin J et al (2001) Non-Hodgkin’s lymphoma after primary Hodgkin’s disease in the German Hodgkin’s Lymphoma Study Group: incidence, treatment, and prognosis. J Clin Oncol 19:2026–2032
Schlembach PJ, Wilder RB, Jones D et al (2002) Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J 8:377–383
Sieber M, Bredenfeld H, Josting A et al (2003) 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: results of a pilot study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:1734–1739
Travis LB, Gospodarowicz M, Curtis RE et al (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94:182–192
Valagussa P, Santoro A, Fossati-Bellani F et al (1986) Second acute leukemia and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol 4:830–837
van der Kaaij MA, Heutte N, Le SN et al (2007) Gonadal function in males after chemotherapy for early-stage Hodgkin’s lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 25:2825–2832
van der Kaaij MAE, van Echten-Arends J, Simons AHM et al (2010) Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol
Younes A, Forero-Torres A, Bartlett NL et al (2008) Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood 112:370
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Batra, A., Portlock, C.S. (2011). Principles of Chemotherapy in Hodgkin Lymphoma. In: Specht, L., Yahalom, J. (eds) Radiotherapy for Hodgkin Lymphoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78944-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-540-78944-4_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-78455-5
Online ISBN: 978-3-540-78944-4
eBook Packages: MedicineMedicine (R0)